Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

The Canadian Cancer Trials Group SR.6 trial (SARC021) -- A Randomized Phase III, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma -- was officially closed to further accrual as of December 26, 2013.

This trial has met its accrual goal.

Thanks to all participating centres, staff and patients for their contributions to this trial.